更新于：2024-11-04
Glyburide/Metformin Hydrochloride
二甲双胍格列本脲
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 Glibenclamide/metformin、Glucovance、Glyburide/metformin + [48] |
作用机制 PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂)、SUR1抑制剂(磺酰脲类受体1抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C27H40Cl2N8O5S |
InChIKeyHCEQQASHRRPQFE-UHFFFAOYSA-N |
CAS号338752-31-1 |
关联
13
项与 二甲双胍格列本脲 相关的临床试验二甲双胍格列本脲片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV
三门峡赛诺维制药有限公司生产的二甲双胍格列本脲片（Ⅱ）（500 mg/5 mg）与Merk SANTE S.A.S 持证的二甲双胍格列本脲片（商品名：GlucovanceTM，500 mg/5 mg）在健康受试者中的单次给药、随机、开放、两周期、双交叉、空腹及餐后状态下的生物等效性研究
100 项与 二甲双胍格列本脲 相关的临床结果
登录后查看更多信息
100 项与 二甲双胍格列本脲 相关的转化医学
登录后查看更多信息
100 项与 二甲双胍格列本脲 相关的专利（医药）
登录后查看更多信息
21
项与 二甲双胍格列本脲 相关的文献（医药）2023-05-01Clinical pharmacology in drug development
Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
Article
作者: Chen, Lin ; Huang, Xiaolun ; Li, Xinjing ; Huang, Jiao
Abstract:
The rational combination of oral antidiabetic agents is more likely to provide better glycemic control than monotherapy. Metformin glibenclamide tablets can be used as second‐line therapy for patients with type 2 diabetes mellitus who cannot successfully control their blood glucose levels by diet and exercise plus metformin or sulfonylureas. The aim of this study was to evaluate the bioequivalence and safety of metformin hydrochloride and glibenclamide tablets (500 mg/5 mg) prepared by 2 different vendors in healthy Chinese subjects under fasting and fed conditions. This is an open‐label, single‐center, randomized, 2‐formulation, 2‐period crossover study. After screening, 40 subjects were enrolled in the fasting trial, while 40 subjects were enrolled in the fed trial. Qualified subjects were randomly assigned to receive a monotherapy dose of 500 mg/5 mg of the test or reference formulation, and after a 1‐week washout period, they took the alternative formulation. Blood samples were collected from 24 blood collection sites per cycle for pharmacokinetic analysis until 36 hours after oral administration. In total, 78 subjects completed the study. Under fasting and fed conditions, the geometric mean ratios of maximum plasma concentration, area under the plasma concentration–time curve (AUC) from time 0 to time of last quantifiable drug level , and AUC from time 0 to infinity between the 2 products, as well as the corresponding 90%CIs, were all within the range of 80%–125%. It was found that exposure (AUC from time 0 to infinity) to metformin is decreased by about 25% in the fed state compared to fasting, whereas glibenclamide exposure is increased by about 30% in the fed state. No severe adverse events were observed in the study.
2019-01-01Acta endocrinologica (Bucharest, Romania : 2005)4区 · 医学
The Effect of Glucovance Therapy on Biomechanical Deterioration of Bone in Streptozotocin-Induced Diabetic Rats
4区 · 医学
Article
作者: Yildiz, A ; Demirel, C ; Gurgul, S ; Akarsu, E ; Erdal, N ; Korkmaz, H
AIM:
Is to evaluate the influence of glucovance therapy on biomechanical properties of bone in streptozotocin - induced diabetes mellitus (DM) in rats.
MATERIALS AND METHODS:
A total of 28 male Wistar-Albino rats (12-week-old; 210-300 g) were divided into 4 groups including control (C; no treatment; n=7), sham [Sh; distilled water (gavage, for 8 weeks); n=7], diabetes [DM; streptozotocin (45 mg/kg, single i.p injection); n=7] and diabetes+ Glucovance treatment [DM+G; streptozotocin (45 mg/kg, single i.p injection) + Glucovance (Glucovance, 500/5 mg/kg/day/rat, gavage, for 8 weeks); n=7] groups. Body weight, blood glucose levels (BGLs), bone mineral density (BMD) and geometric/mechanical properties of bone tissue were evaluated. BGLs in diabetic rats were significantly increased compared to non-diabetic rats, while the body weights were decreased (p<0.05).
RESULTS:
A significant difference was not detected between groups with regard to cross-sectional area of diaphyseal femur (p>0.05). Maximum load, energy absorption capacity, ultimate stress, ultimate strain, toughness and displacement were shown to decrease and stiffness was shown to increase in DM rats (p<0.05). Ultimate stress and maximum load were significantly increased in DM+G groups compared to DM groups (p<0.05).
CONCLUSION:
Glucovance treatment seems to be effective in restoration of biomechanical deterioration of bone specific to STZ-induced DM.
2016-09-01Journal of hypertension2区 · 医学
OS 02-06 PHYSIOLOGICAL REGULATION OF VASOMOTION BY INTRACELLULAR ATP-MEDIATED SYSTEM IN HUMAN ARTERY
2区 · 医学
Article
作者: Kim, Dae Hoon ; Lee, Sang Jin ; Kim, Chan Hyung ; Lee, Sang Eok ; Choi, Woong ; Kim, Young Chul ; Yun, Hyo-Yung
OBJECTIVE:
Spontaneous oscillation of tone of blood vessel called vasomotion cause vessel to flow blood which is an oscillation of flow into an organ. Microcirculation is sensitive to hypoxic condition and metabolism but mechanism of vasomotion is still poorly understood.
DESIGN AND METHOD:
Purpose: We studied involvement of metabolism-mediated regulation by intracellular ATP level of vasomotion in human gastric artery.
METHODS:
Conventional contractile measuring system and Western blot were used.
RESULTS:
Circular muscle of human gastric artery produced sustained tonic contraction of 1.0 ± 0.19 g by 50 mM high K (n = 36). Pinacidil (10 μM), which is known to activatorof ATP-sensitive K (KATP) channel inhibited vasomotion completely in a reversible manner. Inhibition of vasomotion by activators of KATP channel recovered by glibenclamide. Diazoxide (300 μM), cromakalim (10 μM) nicorandil (10 μM) which is known to activate KATP channel also completely blocked vasomotion in a glibenclamide sensitive manner. Inhibitory effect of these openers of KATP channel on serotonin and norepinephrine-induced contraction were also recoded in a glibenclmide-sensitive manner. In human artery, glucose-free condition which is elated metabolic changes inhibited vasomotion and it was recovered by glibenclamide. Finally, molecular subtypes of KATP channel was defined by Western blot in human artery.
CONCLUSIONS:
Vasomotion of human gastroepiploic artery was inhibited by activation of specific subtypes of KATP channel and alteration of metabolism.
100 项与 二甲双胍格列本脲 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2000-07-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 60 | (Glyburide Metformin) | 鹽餘齋窪醖鬱構顧範蓋(淵網壓蓋網膚繭膚觸壓) = 窪艱簾觸遞淵鬱鏇鏇淵 繭繭襯窪構選鹹糧製衊 (衊糧遞淵衊襯鬱製衊製, 網膚夢簾製繭廠襯顧衊 ~ 構膚鬱獵觸襯積鑰齋鹹) 更多 | - | 2009-08-04 | |
(Glucovance®) | 鹽餘齋窪醖鬱構顧範蓋(淵網壓蓋網膚繭膚觸壓) = 製窪衊遞艱範衊襯觸膚 繭繭襯窪構選鹹糧製衊 (衊糧遞淵衊襯鬱製衊製, 餘憲窪齋衊艱網構窪餘 ~ 憲遞夢顧鹽選鹽鹹築蓋) 更多 | ||||||
临床1期 | - | 60 | (Glyburide Metformin) | 願鏇鑰壓糧鹽艱製淵夢(蓋鬱構醖窪蓋繭鏇蓋糧) = 壓鑰餘醖鬱鏇構鏇醖鏇 製艱遞製製淵築範鑰醖 (膚獵鑰膚衊築簾製餘願, 鹽夢鏇鏇艱鹽齋窪蓋膚 ~ 鏇網艱觸鹽築網夢觸築) 更多 | - | 2009-08-04 | |
(Glucovance®) | 願鏇鑰壓糧鹽艱製淵夢(蓋鬱構醖窪蓋繭鏇蓋糧) = 選壓膚夢觸簾繭簾淵蓋 製艱遞製製淵築範鑰醖 (膚獵鑰膚衊築簾製餘願, 遞顧襯壓醖獵襯襯鹽鬱 ~ 餘積觸窪艱憲夢餘積觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用